NasdaqGS:NVAXBiotechs
Assessing Novavax (NVAX) Valuation As Licensing Pivot And Key Vaccine Readout Approach
Novavax (NVAX) is in the spotlight after shifting from COVID-era vaccine production to an asset-light licensing model built around partners such as Sanofi and Pfizer, with investors watching upcoming earnings and a key Phase 3 vaccine readout.
See our latest analysis for Novavax.
The share price has been choppy, with a 1-month share price return of 4.42% and a year to date share price return of 12.76%, while the 1-year total shareholder return is 25.43%. However, the 5-year total shareholder...